These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24389446)

  • 1. Choroidal metastases responsive to crizotinib therapy in a lung adenocarcinoma patient with ALK 2p23 fusion identified by ALK immunohistochemistry.
    Feng Y; Singh AD; Lanigan C; Tubbs RR; Ma PC
    J Thorac Oncol; 2013 Dec; 8(12):e109-11. PubMed ID: 24389446
    [No Abstract]   [Full Text] [Related]  

  • 2. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK.
    Sun JM; Choi YL; Won JK; Hirsch FR; Ahn JS; Ahn MJ; Park K
    J Thorac Oncol; 2012 Dec; 7(12):e36-e38. PubMed ID: 23154564
    [No Abstract]   [Full Text] [Related]  

  • 3. Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation.
    Toyokawa G; Takenoyama M; Watanabe S; Toyozawa R; Inamasu E; Kojo M; Shiraishi Y; Morodomi Y; Takenaka T; Hirai F; Yamaguchi M; Taguchi K; Seto T; Ichinose Y
    J Thorac Oncol; 2013 Nov; 8(11):e96-8. PubMed ID: 24128725
    [No Abstract]   [Full Text] [Related]  

  • 4. Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.
    Peled N; Zach L; Liran O; Ilouze M; Bunn PA; Hirsch FR
    J Thorac Oncol; 2013 Dec; 8(12):e112-3. PubMed ID: 24389447
    [No Abstract]   [Full Text] [Related]  

  • 5. BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.
    Shan L; Jiang P; Xu F; Zhang W; Guo L; Wu J; Zeng Y; Jiao Y; Ying J
    J Thorac Oncol; 2015 Jun; 10(6):e37-9. PubMed ID: 26001147
    [No Abstract]   [Full Text] [Related]  

  • 6. Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
    Pilotto S; Bria E; Peretti U; Massari F; Garassino M; Pelosi G; Tortora G
    J Thorac Oncol; 2013 Dec; 8(12):e105-6. PubMed ID: 24389444
    [No Abstract]   [Full Text] [Related]  

  • 7. Activity of crizotinib over choroidal metastases in non-small-cell lung cancer (NSCLC)-ALK rearranged: a case report.
    Bearz A; Santarossa S; Manfrè A; Beltrame G; Urbani M; Sartor I; Da Ros V; Tirelli U
    BMC Res Notes; 2014 Sep; 7():589. PubMed ID: 25178493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma.
    Rosoux A; Pauwels P; Duplaquet F; D'Haene N; Weynand B; Delos M; Menon R; Heukamp LC; Thunnissen E; Ocak S
    Lung Cancer; 2016 Aug; 98():118-121. PubMed ID: 27393517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.
    Ren S; Hirsch FR; Varella-Garcia M; Aisner DL; Boyle T; Zhou C; Camidge DR
    J Thorac Oncol; 2014 Mar; 9(3):e21-3. PubMed ID: 24518095
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer.
    Browning ET; Weickhardt AJ; Camidge DR
    J Thorac Oncol; 2013 Mar; 8(3):e21. PubMed ID: 23407562
    [No Abstract]   [Full Text] [Related]  

  • 11. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
    J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.
    Lu S; Azada MC; Ou SH
    Lung Cancer; 2015 Feb; 87(2):207-9. PubMed ID: 25558789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors.
    Levacq D; D'Haene N; de Wind R; Remmelink M; Berghmans T
    Lung Cancer; 2016 Dec; 102():38-41. PubMed ID: 27987586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.
    Campos-Gomez S; Lara-Guerra H; Routbort MJ; Lu X; Simon GR
    Int J Biol Markers; 2015 May; 30(2):e254-7. PubMed ID: 25588859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
    Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O
    J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma.
    Caumont C; Veillon R; Gros A; Laharanne E; Bégueret H; Merlio JP
    Lung Cancer; 2016 Feb; 92():15-8. PubMed ID: 26775590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
    Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ
    J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824
    [No Abstract]   [Full Text] [Related]  

  • 18. ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma.
    Ilie M; Long E; Butori C; Hofman V; Coelle C; Mauro V; Zahaf K; Marquette CH; Mouroux J; Paterlini-Bréchot P; Hofman P
    Ann Oncol; 2012 Nov; 23(11):2907-2913. PubMed ID: 22735679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement.
    Maillet D; Martel-Lafay I; Arpin D; Pérol M
    J Thorac Oncol; 2013 Apr; 8(4):e30-1. PubMed ID: 23486270
    [No Abstract]   [Full Text] [Related]  

  • 20. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.
    Yang JJ; Zhang XC; Su J; Xu CR; Zhou Q; Tian HX; Xie Z; Chen HJ; Huang YS; Jiang BY; Wang Z; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Mok TS; Wu YL
    Clin Cancer Res; 2014 Mar; 20(5):1383-92. PubMed ID: 24443522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.